Drug Discontinuation Requirements Would Be Expanded Under DeWine Bill

Manufacturers that intend to discontinue drugs or biologics would have to notify FDA even if the products to be discontinued are multi-source, under a bill introduced by Sen. Mike DeWine (D-Ohio)